-
3 days ago | 
healio.com | Anthony DeFino
Key takeaways: Home OCT may help patients achieve extended dosing intervals through consistent fluid evaluation. Scans are reviewed by AI through a cloud-based platform and by the ophthalmologist. FORT LAUDERDALE, Fla. — Home OCT offers personalized insights on treatment response for wet age-related macular degeneration that may help reduce treatment burden, according to a speaker.
-
4 days ago | 
healio.com | Anthony DeFino
Key takeaways: The Unity platform consists of a vitreoretinal cataract system and a stand-alone cataract system. It improves followability and increases efficiency while using less energy. LOS ANGELES — With the recently launched Unity system, Alcon aims to allow ophthalmologists to perform vitreoretinal cataract surgery and cataract surgery on the same platform.
-
5 days ago | 
healio.com | Brandon D. Ayres |Anthony DeFino |Nancy Hemphill
KIAWAH ISLAND, S.C. — Povicaine, launched in late 2024, has “become a staple in our practice,” Brandon D. Ayres, MD, said in this Healio Video Perspective from Kiawah Eye. Ayres, who practices in the greater Philadelphia area at Wills Eye Hospital and Ophthalmic Partners, uses Povicaine (povidone-iodine 1.25% and proparacaine 0.5%, ImprimisRx) in procedures such as collagen cross-linking, superficial keratectomy, lamellar keratectomy and suture removal.
-
1 week ago | 
healio.com | Anthony DeFino
Key takeaways: Visual acuity improved across seven techniques for secondary IOL implantation. Factors associated with better outcomes were use of the Yamane technique, younger age and time since surgery. KIAWAH ISLAND, S.C. — Secondary IOL implantation improved visual acuity over time across several types of techniques, according to a speaker.
-
1 week ago | 
healio.com | Anthony DeFino
Key takeaways: OCU410ST is designed to treat ABCA4-associated retinopathies. Ocugen anticipates a biologics license application filing in 2027. The FDA granted rare pediatric disease designation for OCU410ST, a gene therapy designed to treat ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 and cone-rod dystrophy 3, according to Ocugen.
-
1 week ago | 
healio.com | Jennifer Loh |Anthony DeFino
LOS ANGELES — At the American Society of Cataract and Refractive Surgery meeting, Jennifer M. Loh, MD, discussed 24-month data investigating TearCare, a localized heat therapy treatment for dry eye disease, compared with Restasis. Stage 1 of the SAHARA trial found that outcomes in patients randomly assigned to treatment with TearCare (Sight Sciences) were superior in terms of tear breakup time and meibomian gland secretion scores vs. Restasis (cyclosporine ophthalmic emulsion 0.05%, AbbVie).
-
2 weeks ago | 
healio.com | Anthony DeFino
Key takeaways: The approval is based on positive 1-year data from the phase 3 Pavilion study. This is Susvimo’s third FDA-approved indication. The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.
-
2 weeks ago | 
healio.com | Anthony DeFino
Key takeaways: Qdata Cataracts includes real-world data from more than 9 million patients. Verana Health aims to optimize care by collecting data on surgical techniques, IOLs and patient characteristics. Verana Health launched a real-world dataset on cataract surgery outcomes, according to a press release.
-
2 weeks ago | 
healio.com | William Trattler |Anthony DeFino
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
-
3 weeks ago | 
healio.com | Michael Singer |Anthony DeFino
FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD,discusses promising results for migaldendranib for the treatment of wet age-related macular degeneration and diabetic macular edema. The subcutaneous injection is a tyrosine kinase inhibitor designed to block all forms of VEGF, Singer explained at the Retina World Congress. A study investigated migaldendranib (Ashvattha Therapeutics) given monthly and every 2 weeks.
